(Q38465854)

3 September 2017

1 reference

title

Molecular targets in glioblastoma (English)

1 reference

3 September 2017

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Antonio Caretta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Maira Zorzan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Enrico Giordan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Carla Mucignat-Caretta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

1 January 2015

1 reference

3 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

1407-1420

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

The 2007 WHO classification of tumours of the central nervous system

11 June 2020

cites work

1 reference

21 January 2018

On the origin of glioma

1 reference

Molecular pathology of malignant gliomas

21 January 2018

1 reference

The new WHO classification of brain tumours

21 January 2018

1 reference

Current concepts and management of glioblastoma

21 January 2018

1 reference

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

21 January 2018

1 reference

Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro

21 January 2018

1 reference

Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting

21 January 2018

1 reference

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma

21 January 2018

1 reference

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine

21 January 2018

1 reference

Standard therapy for glioblastoma--a review of where we are.

21 January 2018

1 reference

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma

21 January 2018

1 reference

Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients

21 January 2018

1 reference

Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells

21 January 2018

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

Molecular pathology and clinical characteristics of oligodendroglial neoplasms.

21 January 2018

1 reference

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

21 January 2018

1 reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function

21 January 2018

1 reference

D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function

21 January 2018

1 reference

An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

21 January 2018

1 reference

Current trends in targeted therapies for glioblastoma multiforme

21 January 2018

1 reference

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

21 January 2018

1 reference

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

Extensive modulation of a set of microRNAs in primary glioblastoma

21 January 2018

1 reference

microRNA-34a is tumor suppressive in brain tumors and glioma stem cells

21 January 2018

1 reference

Oncomirs - microRNAs with a role in cancer

21 January 2018

1 reference

MicroRNA expression and function in cancer

21 January 2018

1 reference

21 January 2018

1 reference

The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo

21 January 2018

1 reference

MicroRNAs involved in the EGFR/PTEN/AKT pathway in gliomas

21 January 2018

1 reference

Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status

21 January 2018

1 reference

PTEN modulators: a patent review

21 January 2018

1 reference

Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

21 January 2018

1 reference

Targeting mTOR in cancer: renal cell is just a beginning

21 January 2018

1 reference

The Notch signaling pathway: molecular basis of cell context dependency

21 January 2018

1 reference

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies

21 January 2018

1 reference

Identification of a tumour suppressor network opposing nuclear Akt function

21 January 2018

1 reference

PML regulates p53 stability by sequestering Mdm2 to the nucleolus

21 January 2018

1 reference

Transcriptional repression by the promyelocytic leukemia protein, PML.

21 January 2018

1 reference

Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway

21 January 2018

1 reference

Genetic pathways to glioblastoma: a population-based study

21 January 2018

1 reference

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

21 January 2018

1 reference

Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges

21 January 2018

1 reference

Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.

21 January 2018

1 reference

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence

21 January 2018

1 reference

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors

21 January 2018

1 reference

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

21 January 2018

1 reference

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

21 January 2018

1 reference

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

21 January 2018

1 reference

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

21 January 2018

1 reference

Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab

21 January 2018

1 reference

Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments

21 January 2018

1 reference

Epidermal growth factor receptor: a re-emerging target in glioblastoma

21 January 2018

1 reference

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR.

21 January 2018

1 reference

Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo

21 January 2018

1 reference

Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.

21 January 2018

1 reference

Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation

21 January 2018

1 reference

Epidermal growth factor receptor as a therapeutic target in glioblastoma

21 January 2018

1 reference

Notch signalling: a simple pathway becomes complex

21 January 2018

1 reference

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells

21 January 2018

1 reference

Targeting Notch to target cancer stem cells.

21 January 2018

1 reference

Noninvasive and real-time assessment of reconstructed functional human endometrium in NOD/SCID/gamma c(null) immunodeficient mice

21 January 2018

1 reference

Expression of the neural RNA-binding protein Musashi1 in human gliomas

21 January 2018

1 reference

Expression of the Neural RNA-binding protein Musashi1 in pediatric brain tumors

21 January 2018

1 reference

CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2).

21 January 2018

1 reference

The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA

21 January 2018

1 reference

Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation

21 January 2018

1 reference

Retracted: The Different Role of Notch1 and Notch2 in Astrocytic Gliomas

21 January 2018

1 reference

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

21 January 2018

1 reference

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited

21 January 2018

1 reference

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

21 January 2018

1 reference

A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.

21 January 2018

1 reference

Molecular events implicated in brain tumor angiogenesis and invasion

21 January 2018

1 reference

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

21 January 2018

1 reference

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

21 January 2018

1 reference

Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2

21 January 2018

1 reference

Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion

21 January 2018

1 reference

Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure.

21 January 2018

1 reference

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

21 January 2018

1 reference

Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment

21 January 2018

1 reference

Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations

21 January 2018

1 reference

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma

21 January 2018

1 reference

A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas

21 January 2018

1 reference

A phase I/II trial of vandetanib for patients with recurrent malignant glioma

21 January 2018

1 reference

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide

21 January 2018

1 reference

A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma

21 January 2018

1 reference

Continuous daily sunitinib for recurrent glioblastoma

21 January 2018

1 reference

Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

21 January 2018

1 reference

Hedgehog signaling in animal development: paradigms and principles

21 January 2018

1 reference

Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway

21 January 2018

1 reference

Smoothing out drug resistance.

21 January 2018

1 reference

Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations

21 January 2018

1 reference

HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity

21 January 2018

1 reference

Hedgehog pathway as a drug target: Smoothened inhibitors in development

21 January 2018

1 reference

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

21 January 2018

1 reference

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists

21 January 2018

1 reference

Selective distribution of protein kinase A regulatory subunit RII{alpha} in rodent gliomas.

21 January 2018

1 reference

Overexpression of RII beta regulatory subunit of protein kinase A in human colon carcinoma cell induces growth arrest and phenotypic changes that are abolished by site-directed mutation of RII beta

21 January 2018

1 reference

Protein kinase A regulatory subunits in colon cancer

21 January 2018

1 reference

Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines

21 January 2018

1 reference

PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma.

21 January 2018

1 reference

Interaction of PACAP with Sonic hedgehog reveals complex regulation of the hedgehog pathway by PKA.

21 January 2018

1 reference

Cholera toxin induces malignant glioma cell differentiation via the PKA/CREB pathway.

21 January 2018

1 reference

Transcriptional and post-transcriptional down-regulation of cyclin D1 contributes to C6 glioma cell differentiation induced by forskolin

21 January 2018

1 reference

Caffeine inhibits cell proliferation and regulates PKA/GSK3β pathways in U87MG human glioma cells

21 January 2018

1 reference

Protein kinase A regulatory subunit distribution in medulloblastoma

21 January 2018

1 reference

EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180.

21 January 2018

1 reference

Escaping from the TGFbeta anti-proliferative control

21 January 2018

1 reference

21 January 2018

1 reference

The role of transforming growth factor-beta in primary brain tumors

21 January 2018

1 reference

Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells

21 January 2018

1 reference

Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape

21 January 2018

1 reference

TGF-β as a therapeutic target in high grade gliomas - promises and challenges.

21 January 2018

1 reference

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β.

21 January 2018

1 reference

Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

21 January 2018

1 reference

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

21 January 2018

1 reference

Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

21 January 2018

1 reference

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

21 January 2018

1 reference

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

21 January 2018

1 reference

Integrin control of the transforming growth factor-β pathway in glioblastoma.

21 January 2018

1 reference

Acetate is a bioenergetic substrate for human glioblastoma and brain metastases

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.15.22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25952786%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference